AR and benign prostatic hyperplasia: Androgen ablation therapy, such as the use of finasteride, dutasteride and other 5α‐reductase inhibitors (5‐ARIs), can impair AR signalling by inhibiting the production of dihydrotestosterone (DHT).2 Reducing androgen levels has been universally recognized as an effective method for treating BPH by inducing prostate epithelial cell apoptosis.3 However, clinical progression still occurs in more than 17% of BPH patients who receive long‐term 5‐ARI treatment, and the detailed molecular and cellular mechanisms remain to be determined.4, 5